Skip to main content

Bank of America Securities Keeps Their Buy Rating on Supernus Pharmaceuticals (SUPN)

Tipranks - Tipranks - Thu Jan 8, 5:52AM CST

Bank of America Securities analyst Pavan Patel reiterated a Buy rating on Supernus Pharmaceuticals today and set a price target of $65.00.

Claim 70% Off TipRanks Premium

According to TipRanks, Patel is ranked #7072 out of 10149 analysts.

Currently, the analyst consensus on Supernus Pharmaceuticals is a Strong Buy with an average price target of $61.33.

See the top stocks recommended by analysts >>

Based on Supernus Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $192.1 million and a GAAP net loss of $45.12 million. In comparison, last year the company earned a revenue of $175.69 million and had a net profit of $38.5 million

Based on the recent corporate insider activity of 69 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SUPN in relation to earlier this year. Most recently, in October 2025, Jack Khattar, the President & CEO of SUPN sold 59,900.00 shares for a total of $3,029,336.39.

Read More on SUPN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).